Analysts Anticipate Spark Therapeutics Inc (ONCE) Will Post Quarterly Sales of $21.86 Million

Wall Street analysts expect Spark Therapeutics Inc (NASDAQ:ONCE) to report $21.86 million in sales for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Spark Therapeutics’ earnings, with the lowest sales estimate coming in at $14.45 million and the highest estimate coming in at $25.40 million. Spark Therapeutics posted sales of $15.68 million in the same quarter last year, which would indicate a positive year over year growth rate of 39.4%. The company is scheduled to issue its next quarterly earnings report on Tuesday, May 14th.

According to Zacks, analysts expect that Spark Therapeutics will report full-year sales of $115.14 million for the current year, with estimates ranging from $72.47 million to $157.06 million. For the next fiscal year, analysts anticipate that the business will post sales of $142.74 million, with estimates ranging from $91.10 million to $238.58 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that that provide coverage for Spark Therapeutics.

Spark Therapeutics (NASDAQ:ONCE) last posted its earnings results on Tuesday, February 19th. The biotechnology company reported ($1.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.89). The firm had revenue of $13.15 million for the quarter, compared to analyst estimates of $26.76 million. Spark Therapeutics had a negative net margin of 121.78% and a negative return on equity of 14.66%. The company’s revenue for the quarter was up 47.9% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.63) earnings per share.

ONCE has been the subject of a number of research analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $80.00 price target (down from $103.00) on shares of Spark Therapeutics in a research note on Thursday, January 10th. B. Riley raised shares of Spark Therapeutics from a “neutral” rating to a “buy” rating and upped their price target for the stock from $68.00 to $71.00 in a research note on Wednesday, November 7th. Credit Suisse Group reaffirmed a “hold” rating and issued a $44.00 price target on shares of Spark Therapeutics in a research note on Monday, January 7th. Raymond James reaffirmed a “buy” rating on shares of Spark Therapeutics in a research note on Monday, November 26th. Finally, Mizuho reduced their price target on shares of Spark Therapeutics to $62.00 and set a “buy” rating for the company in a research note on Wednesday, November 7th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and twelve have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $65.35.

Several hedge funds have recently added to or reduced their stakes in the company. Macquarie Group Ltd. raised its holdings in shares of Spark Therapeutics by 22.3% during the fourth quarter. Macquarie Group Ltd. now owns 622,389 shares of the biotechnology company’s stock valued at $24,360,000 after acquiring an additional 113,533 shares during the period. Great Point Partners LLC raised its holdings in shares of Spark Therapeutics by 60.4% during the fourth quarter. Great Point Partners LLC now owns 630,600 shares of the biotechnology company’s stock valued at $24,682,000 after acquiring an additional 237,453 shares during the period. Legal & General Group Plc raised its holdings in shares of Spark Therapeutics by 36.7% during the fourth quarter. Legal & General Group Plc now owns 14,083 shares of the biotechnology company’s stock valued at $551,000 after acquiring an additional 3,782 shares during the period. Jane Street Group LLC acquired a new stake in shares of Spark Therapeutics during the fourth quarter valued at approximately $378,000. Finally, Metropolitan Life Insurance Co. NY raised its holdings in shares of Spark Therapeutics by 356.7% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 10,207 shares of the biotechnology company’s stock valued at $400,000 after acquiring an additional 7,972 shares during the period.

Shares of NASDAQ:ONCE traded down $0.28 during trading on Friday, reaching $50.61. The company had a trading volume of 534,100 shares, compared to its average volume of 471,089. The firm has a market cap of $1.88 billion, a P/E ratio of -23.99 and a beta of 2.06. Spark Therapeutics has a twelve month low of $34.53 and a twelve month high of $96.59. The company has a current ratio of 10.71, a quick ratio of 10.36 and a debt-to-equity ratio of 0.09.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia.

Further Reading: Google Finance Portfolio Tips and Tricks

Get a free copy of the Zacks research report on Spark Therapeutics (ONCE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit